Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036894 · ClinicalTrials.gov registry record · Phase 1
CC-5013 in Treating Patients With Recurrent Glioma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00036894: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00036894 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00036894, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: CC-5013 may stop the growth of gliomas by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have recurrent glioma.
Interventions
- DRUG lenalidomide
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00036894
The ClinicalTrials.gov registry entry for NCT00036894 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lenalidomide is the first listed.
NCT00036894 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00036894 about?
NCT00036894 is a clinical study titled "CC-5013 in Treating Patients With Recurrent Glioma". RATIONALE: CC-5013 may stop the growth of gliomas by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have recurrent glioma.
What is the current status of trial NCT00036894?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-03.
What interventions are being tested in trial NCT00036894?
The interventions under investigation include: lenalidomide (DRUG).
Who is sponsoring clinical trial NCT00036894?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.